Skip to main content
. Author manuscript; available in PMC: 2010 Jan 5.
Published in final edited form as: Int J Pharm. 2008 Aug 27;365(1-2):157–161. doi: 10.1016/j.ijpharm.2008.08.024

Figure 3. GI50 (concentration of drug at which 50% growth inhibition is seen) of various 17-allylamino-17-demethoxy geldanamycin formulations to MCF-7 human breast cancer cells*.

Figure 3

*Data are means±SD after 72-h incubation (each data point, n=3 experiments). +P<0.05 in comparison to 17-AAG-SSM.

17-AAG, 17-allylamino-17-demethoxy geldanamycin; SSM; sterically stabilized nanomicelles; VIP, vasoactive intestinal peptide; DMSO, dimethylsulfoxide